Difference between revisions of "WSI21-133"

From MGH Learn Pathology
(Created page with "{{dziOrderStudySet |order_date=July 06, 2021 01:07:32 PM |user=Em99 |class_name=Study Set |status=Created |collection_name=Cytopathology |class_type=Cytology |collection_topic...")
 
(Edited automatically from page learn:wsidashboard.)
 
(62 intermediate revisions by 10 users not shown)
Line 1: Line 1:
−
{{dziOrderStudySet
+
{{ServiceRequest
−
|order_date=July 06, 2021 01:07:32 PM
+
|intent=order
−
|user=Em99
+
|category=409073007
−
|class_name=Study Set
+
|priority=routine
−
|status=Created
+
|code=study
−
|collection_name=Cytopathology
+
|orderDetail=order
−
|class_type=Cytology
+
|authoredOn=July 06, 2021 01:07:32 PM
−
|collection_topic=Urine and Bladder Washings
+
|requester=Em99
−
|requested_by=IAC
+
|locationCode=learn
−
|restrict_access=Public
+
|access=public
 +
|subject=MGH
 +
|performer=MGH
 +
|supportingInfo=Cytology
 +
|requisition=Cytology
 +
|reasonCode=Urine and Bladder Washings
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-133
 +
|requester=Si787
 +
|authoredOn=March 10, 2022 10:38:24 AM
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Sj82
 +
|authoredOn=Jul 22, 2022 10:25:41
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Jul 22, 2022 12:21:09
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Jul 22, 2022 12:21:35
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Jul 22, 2022 12:23:41
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Jul 22, 2022 12:23:49
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Cfh13
 +
|authoredOn=Aug 10, 2022 20:35:36
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Aug 11, 2022 13:24:32
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Aug 11, 2022 13:46:12
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Aug 12, 2022 12:47:16
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Aug 12, 2022 20:13:05
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Cfh13
 +
|authoredOn=Aug 19, 2022 19:51:38
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-133
 +
|requester=Cfh13
 +
|authoredOn=Aug 19, 2022 20:13:24
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Aug 23, 2022 18:08:14
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Aug 23, 2022 18:18:15
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Sep 02, 2022 15:11:25
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Mlz8
 +
|authoredOn=Oct 28, 2022 20:50:26
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-133
 +
|requester=Mlz8
 +
|authoredOn=Oct 28, 2022 20:52:47
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Oct 31, 2022 19:26:26
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Nov 04, 2022 13:39:54
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Nov 14, 2022 17:23:32
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Cfh13
 +
|authoredOn=Nov 16, 2022 18:08:26
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-133
 +
|requester=Cfh13
 +
|authoredOn=Dec 16, 2022 20:58:23
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Dec 19, 2022 21:11:06
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Dec 19, 2022 21:12:12
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Dec 21, 2022 17:56:50
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Cfh13
 +
|authoredOn=Feb 13, 2023 14:14:27
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Cfh13
 +
|authoredOn=Feb 13, 2023 14:14:27
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-133
 +
|requester=Cfh13
 +
|authoredOn=Feb 13, 2023 14:17:45
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Feb 13, 2023 17:34:40
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Cfh13
 +
|authoredOn=Feb 16, 2023 15:19:29
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-133
 +
|requester=Cfh13
 +
|authoredOn=Feb 16, 2023 15:22:04
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Ndk6
 +
|authoredOn=Feb 17, 2023 22:39:14
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Feb 27, 2023 15:37:24
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Tz046
 +
|authoredOn=Mar 01, 2023 14:52:41
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Mar 06, 2023 17:34:02
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Mar 06, 2023 17:36:24
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Mar 09, 2023 18:40:33
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=Mar 09, 2023 19:45:59
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Iac0
 +
|authoredOn=Mar 30, 2023 17:46:10
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-133
 +
|requester=Iac0
 +
|authoredOn=Mar 30, 2023 17:46:49
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Iac0
 +
|authoredOn=Mar 30, 2023 17:47:23
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-133
 +
|requester=Iac0
 +
|authoredOn=Mar 30, 2023 17:49:15
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-133
 +
|requester=Mlz8
 +
|authoredOn=Apr 14, 2023 17:59:14
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-133
 +
|requester=Mlz8
 +
|authoredOn=Apr 14, 2023 18:02:22
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=May 01, 2023 18:44:19
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=May 01, 2023 19:02:37
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-133
 +
|requester=Aja51
 +
|authoredOn=May 01, 2023 19:24:35
 
}}
 
}}

Latest revision as of 14:24, May 1, 2023


Request type Study
Subspecialty Cytology
Set Cytology
Topic Urine and Bladder Washings
Presenter MGH


Toggle columns: Diagnosis

Case Clinical history Requester Diagnosis
Case Clinical history Requester Diagnosis

Case 1


78-year-old male. Hematuria. Iac0 Small cell carcinoma.

Case 2


68-year-old male. History of diffuse large B cell lymphoma. Iac0 B-cell lymphoma involving urine.

Case 3


59-year-old male with urinary frequency; voided urine Sj82 Urothelial cells with degenerative changes

Crystals

Starch

Case 4


50 year old man with hematuria and a history of renal calculi. Upper tract urine. Cfh13 Negative for High Grade Urothelial Carcinoma. Reactive urothelial cells.

Case 5


78 year old man with microscopic hematuria. Cfh13 High Grade Urothelial Carcinoma.

Case 6


79 yo man with hematuria. Cfh13 Negative for high grade urothelial carcinoma. Reactive urothelial and squamous cells.

Case 7


75 yo man with a history of urothelial carcinoma treated with BCG. Cfh13 Negative for high grade urothelial carcinoma.

Casts. Benign urothelial cells.

Granulomas consistent with BCG treatment.

Case 8


66 yo woman with hematuria. Cfh13 Atypical.

Red blood cells. Atypical transitional cells • singly and in clusters with degenerative changes.

Degenerated cells with cytopathic changes consistent with Human polyomavirus effect.

Case 9


73 yo man with LUTS. Cfh13 Suspicious for high-grade urothelial carcinoma. Rare highly-atypical transitional cells • suspicious for high-grade urothelial cell carcinoma.

Case 10


70 yo man with remote history of urothelial carcinoma. Cfh13 Suspicious for malignancy. Markedly atypical urothelial cells • suspicious for high-grade urothelial carcinoma.

Case 11


76 yo man with smoking history. Cfh13 Suspicious for malignancy. Atypical urothelial cells • some with degenerative changes.

Case 12


54 yo man with a space filling bladder lesion on imaging. Cfh13 Positive for high-grade urothelial carcinoma.

Case 13


70M with multiple bladder lesions Mlz8 Poorly differentiated carcinoma

Case 14


28 yo F with neurogenic lower urinary tract symptoms and peripheral eosinophilia. Prior bladder biopsy showing eosinophilic cystitis. Cfh13 Negative for High Grade Urothelial carcinoma. Mixed inflammation including eosinophils.

Case 15


73 yo man with a history of urothelial carcinoma and changes on cystoscopy consistent with inflammation. Cfh13 High-grade urothelial carcinoma. Polyomavirus effect.

Case 16


64 yo man with a history of prostate carcinoma. Cfh13 Positive for malignant cells. Metastatic carcinoma • consistent with the patient's prior prostate carcinoma.

Case 17


57 yo male with hematuria Ndk6 High grade urothelial cell carcinoma with squamous differentiation

Case 18


Bladder wash from 75 yo female Ndk6 High grade urothelial cell carcinoma

Case 19


60ish year old female with prior history of tumor in bladder. Tlh39 Metastatic small cell neuroendocrine carcinoma.

Case 20


65 yo M with gross hematuria Tz046 Negative for HGUC. Alternaria conidia.

Case 21


Ileal conduit • history of high-grade urothelial carcinoma. Iac0 Abundant degenerated cells consistent with ileal loop specimen. Guar cells from the Coloplast SenSura Mio ostomy wafer adhesive present.

Case 22


81M Mlz8 LGUN (LGUC on biopsy)

Case 23


86 yo male with history of bladder cancer Ndk6 High-grade urothelial carcinoma

Case 24


66 yo male with new mass noted on recent CT scan Ndk6 High-grade urothelial cell carcinoma

Case 25


84 yo f with history of bladder cancer Ndk6 High-grade urothelial cell carcinoma

Case 26


87 yo m with history of bladder cancer Ndk6 NEGATIVE FOR HIGH GRADE UROTHELIAL CARCINOMA Reactive urothelial cells • neutrophils • red blood cells • bacteria • and fungal organisms morphologically consistent with Candida species.

Case 139


86 yo M Ndk6 High grade urothelial cell carcinoma

Case 140


68 yo M w/ mass noted on recent CT scan Ndk6 High grade urothelial cell carcinoma

Case 141


51-year-old man with hematuria Lt511 papillary clusters of atypical urothelial cells consistent with papillary neoplasia • favor papillary urothelial carcinoma • low grade 1-2

Case 142


86 yo male with hematuria Ndk6 Poorly differentiated carcinoma with neuroendocrine differentiation Note: Immunohistochemistry - tumor cells are focally positive for MNF116 and synaptophysin. They are negative for CD20 and CD3.

Case 143


84-year-old man with hematuria Lt511 High grade urothelial carcinoma with squamous differentiation

Case 144


66 yo male with hematuria Ndk6 High-grade urothelial cell carcinoma

Case 146


26 yo male with hematuria Ndk6 NEGATIVE FOR HIGH GRADE UROTHELIAL CARCINOMA- Neutrophilic and multinucleated giant cell reaction to Schistosomal eggs • consistent with Schistosomiasis

Case 147


66 yo male with hematuria Ndk6 High-grade urothelial cell carcinoma

Case 149


26 yo male with hematuria Ndk6 NEGATIVE FOR HIGH GRADE UROTHELIAL CARCINOMA- Neutrophilic and multinucleated giant cell reaction to Schistosomal eggs • consistent with Schistosomiasis

Case 150


58 yo F Ndk6 NEGATIVE FOR HIGH GRADE UROTHELIAL CARCINOMA

-Urothelial cells.

- Squamous cells and fungal organisms • consistent with cervicovaginal contamination



























Retrieved from "https://learn.mghpathology.org/index.php?title=WSI21-133&oldid=108730"
  • Powered by MediaWiki
  • Search Powered by Cargo
  • Massachusetts General Hospital